Penny stocks are often overlooked by investors due to their volatility. However, some penny stocks have the potential to become very profitable. Notably, with the global cancer drug market estimated to cross $289 billion by 2030, Elevation Oncology (ELEV) is one high-potential penny stock that's gaining attention for its unique approach to addressing unmet medical needs in oncology.
As investors consider the potential of this burgeoning field, Elevation Oncology stock has emerged as an intriguing opportunity with promising developments in its pipeline. This explains the stock's impressive gains so far; ELEV is up an eye-catching 825% year-to-date, far outperforming the S&P 500 Index's ($SPX) 9.7% gain.
